



(51) International Patent Classification:

C07D 239/95 (2006.01) *A61P 37/00* (2006.01)
A61K 31/513 (2006.01) *A61P 29/00* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2013/068866

(22) International Filing Date:

7 November 2013 (07.11.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:


61/723,827 8 November 2012 (08.11.2012) US

(71) Applicant: BRISTOL-MYERS SQUIBB COMPANY
[US/US]; P.O. Box 4000, Route 206 and Province Line
Road, Princeton, New Jersey 08543-4000 (US).(72) Inventors: SANTELLA, Joseph B.; c/o Bristol-Myers
Squibb Company, Route 206 & Province Line Road, Prin-
ceton, New Jersey 08543 (US). MOSLIN, Ryan M.; c/o
Bristol-Myers Squibb Company, Route 206 & Province
Line Road, Princeton, New Jersey 08543 (US). WEIN-
STEIN, David S.; c/o Bristol-Myers Squibb Company,
Route 206 & Province Line Road, Princeton, New Jersey
08543 (US). WROBLESKI, Stephen T.; c/o Bristol-My-
ers Squibb Company, Route 206 & Province Line Road,
Princeton, New Jersey 08543 (US). TOKARSKI, John S.;
c/o Bristol-Myers Squibb Company, Route 206 & Province
Line Road, Princeton, New Jersey 08543 (US).(74) Agents: DUNCAN, Laurelee A. et al.; Bristol-Myers
Squibb Company, P.O. Box 4000, Princeton, New Jersey
08543-4000 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

[Continued on next page]

(54) Title: ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFN α 

(I)

(57) Abstract: Compounds having the following formula (I): or a stereoisomer or pharmaceutically-acceptable salt thereof, where R¹, R², R³, R⁴, and R⁵ are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN α by acting on Tyk-2 to cause signal transduction inhibition.

WO 2014/074670 A1



Published:

— *with international search report (Art. 21(3))*